Press Release: Ethicor Pharma : Phrixus Pharmaceuticals announces Phase 2 clinical trial of Poloxamer 188 NF in non-ambulatory patients with Duchenne muscular dystrophy

Press Release: Ethicor Pharma : Phrixus Pharmaceuticals Receives Services From National Institutes of Health, NHLBI SMARTT Program to Produce Carmeseal-MD(TM) for Clinical Trial to Treat Duchenne Muscular Dystrop

Press Release: Ethicor Pharma : Phrixus Pharmaceuticals Announces European Access Program for Carmeseal-MD (P-188 NF) for Patients With Duchenne Muscular Dystrophy